RxDoctor Payments Data

Philippe Petrus, PA

Physician Assistant · El Paso, TXNPI 1639398035

Payments from drug & device makers

$5,803in general payments, 2019–2025

Across 278 payments — averaging $20.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Neurocrine Biosciences, Inc.$925
  • AbbVie$755
  • Alkermes, Inc.$627
  • Johnson & Johnson$495
  • Otsuka America Pharmaceutical, Inc.$376
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$5,71398%
  • Education$902%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,803 in reported general payments places this provider in the 90th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$57,025
Medicare patients
107
Services billed
739

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate12$42,427
Lurasidone Hcl58$22,242
CaplytaLumateperone Tosylate12$21,725
Paliperidone ErPaliperidone18$6,064
Olanzapine OdtOlanzapine21$4,424
Aripiprazole65$3,760
Oxcarbazepine78$3,691
Quetiapine Fumarate94$1,686
Buspirone Hcl110$1,460
Olanzapine72$1,410
Doxepin Hcl44$1,353
Mirtazapine104$1,263
Trazodone Hcl136$1,091
Eszopiclone22$1,054
Duloxetine Hcl66$1,000

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$495$42,42712 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$1,184$21,72512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →